The Bruton's tyrosine kinase inhibitor ibrutinib in combination with carfilzomib in patients with relapsed or relapsed and refractory multiple myeloma: initial results from a multicenter phase 1/2b study
Year: 2015
Type: article
Institutions: Icahn School of Medicine at Mount Sinai, Medical University of South Carolina, Carolinas Healthcare System, Levine Cancer Institute, University of California, Los Angeles, Weill Cornell Medicine, Colorado Blood Cancer Institute, Duke Medical Center, Virginia Commonwealth University Medical Center, University of Nebraska Medical Center, Cleveland Clinic, The University of Texas Southwestern Medical Center, City Of Hope National Medical Center, Pharmacyclics (United States), Vanderbilt University, Vanderbilt-Ingram Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2318956387